Efficacy of axitinib rechallenge in metastatic renal cell carcinoma.
Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Kenichi Harada, Masato Fujisawa
Author Information
- Kotaro Suzuki: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. ORCID
- Takuto Hara: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
- Tomoaki Terakawa: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
- Kenichi Harada: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
- Masato Fujisawa: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
No abstract text available.
- Motzer RJ, Jonasch E, Michaelson MD et al. NCCN guidelines insights: kidney cancer, version 2.2020. J. Natl. Compr. Canc. Netw. 2019; 17: 1278-85.
- Oudard S, Geoffrois L, Guillot A et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) study. Eur. J. Cancer 2016; 62: 28-35.
- Munarriz J, Reynes G, Sanchez-Lorenzo L et al. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. Cancer Chemother. Pharmacol. 2019; 84: 781-9.
- Miyake H, Harada KI, Fujisawa M. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases. Int. Cancer Conf. J. 2018; 7: 30-4.
- Murata M, Ikeda Y, Hasegawa G, Nakagawa Y, Nishiyama T. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon alpha, sunitinib, axitinib, and nivolumab therapies: a case report. J. Med. Case Rep. 2019; 13: 98.
- Nozawa M, Yamamoto Y, Minami T et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int. 2012; 110: E228-34.
- Leung HW, Chan AL, Lin SJ. Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: a network meta-analysis of randomised clinical trials. Mol. Clin. Oncol. 2014; 2: 858-64.
Antineoplastic Agents
Axitinib
Carcinoma, Renal Cell
Humans
Indazoles
Kidney Neoplasms
Protein Kinase Inhibitors
Treatment Outcome
Antineoplastic Agents
Indazoles
Protein Kinase Inhibitors
Axitinib
